Are you Dr. Cabell?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 38 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1000 Trent Drive
Durham, NC 27610Phone+1 919-620-4467- Is this information wrong?
Summary
- Dr. Chris Cabell, MD is a cardiologist in Durham, North Carolina. He is currently licensed to practice medicine in North Carolina.
Education & Training
Duke University HospitalFellowship, Cardiovascular Disease, 1999 - 2002- Duke University HospitalFellowship, Cardiovascular Disease, 1997 - 1998
Duke University School of MedicineClass of 1994
Certifications & Licensure
NC State Medical License 1995 - 2018
Clinical Trials
- A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Start of enrollment: 2019 Sep 23
- Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis Start of enrollment: 2019 Jun 13
- An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Start of enrollment: 2019 Sep 05
Publications & Presentations
PubMed
- 14 citationsRecent developments in the science of proarrhythmic cardiac safety of new drugs.J. Rick Turner, Dilip R. Karnad, Christopher H. Cabell, Snehal Kothari> ;European Heart Journal. Cardiovascular Pharmacotherapy. 2017 Apr 1
- 7 citationsThe Cardiac Safety Research Consortium enters its second decade: An invitation to participate.J. Rick Turner, Peter R. Kowey, Ignacio Rodriguez, Christopher H. Cabell, Gary Gintant, Cynthia L. Green, Barbara Lopez Kunz, Justin Mortara, Philip T. Sager, Norman S...> ;American Heart Journal. 2016 Jul 1
- 63 citationsImpact of Early Valve Surgery on Outcome of Staphylococcus aureus Prosthetic Valve Infective Endocarditis: Analysis in the International Collaboration of Endocarditis–..., , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;Clinical Infectious Diseases. 2015 Mar 1
- Join now to see all
Press Mentions
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided ApproachNovember 14th, 2022- Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus VaccinesNovember 1st, 2022
- Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in the Lancet Infectious DiseasesJune 21st, 2022
- Join now to see all
